UPDATE
Jan 27, 2023, 11.45 AM
Cipla Limited announced its unaudited consolidated financial results for quarter ended December 31st, 2022.
Revenue growth for the quarter was at 6% YoY on a reported basis and a strong 11% YoY ex-covid.
The company posted Robust double-digit traction in core portfolio across therapies and business segments; 11% YoY ex-covid growth.
R&D investments stands at Rs. 363 crores or 6.2 % of sales.
UP NEXT
Read Next